PwPepwise

L-Carnosine

Antioxidants

β-alanyl-L-histidine dipeptide

L-Carnosine is a naturally occurring dipeptide composed of the amino acids beta-alanine and histidine, found abundantly in muscle tissue.

§Dosing at a glance

8 protocols · from the research
What it's forDoseHow oftenHowFor how long
Autism Spectrum Disorder (children)800 mg/day—OralTaken by mouth.12 wks
Type 2 Diabetes / Metabolic Health1,000 mg/day—OralTaken by mouth.12 wks
Schizophrenia / Cognitive Function2,000 mg/day—OralTaken by mouth.24 wks
Gulf War Illness / Cognitive Symptoms500 mg/day—OralTaken by mouth.—
Chronic Heart Failure500 mgOnce dailyOralTaken by mouth.6 mos
Oxaliplatin-Induced Peripheral Neuropathy500 mg/day—OralTaken by mouth.—
Gastrointestinal Protection (aspirin-induced small bowel injury)150 mg/day—OralTaken by mouth.4 wks
Infant Regurgitation500–2,000 mg/day—OralTaken by mouth.12–24 wks

Approximate values pulled from the research — double-check before dosing.

§01Summary

L-Carnosine is a naturally occurring dipeptide composed of the amino acids beta-alanine and histidine, found abundantly in muscle tissue and the brain. The body uses it as an antioxidant, anti-inflammatory agent, and inhibitor of advanced glycation end-products (AGEs) — molecules that accumulate with aging and metabolic disease and can damage proteins and tissues. In plain terms, carnosine helps protect cells from oxidative stress and the kind of molecular "rusting" associated with conditions like diabetes and neurodegeneration.

Human clinical trials have investigated L-Carnosine across a surprisingly broad range of conditions. In children with autism spectrum disorder, 800 mg/day improved behavioral and communication scores compared to placebo1. In adults with type 2 diabetes, 1,000 mg/day reduced fasting blood glucose, HbA1c, triglycerides, and inflammatory markers2. Preliminary evidence suggests it may support executive function in people with schizophrenia3,4, and it appears to improve exercise capacity and quality of life in patients with chronic heart failure6. The zinc-chelated form (zinc L-carnosine, or polaprezinc) has been reported to protect the gut and oral mucosa from chemotherapy- and radiation-related damage7,10. Most studied doses range from 500 mg to 2,000 mg per day and are generally well-tolerated across diverse populations.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

L-Carnosine (β-alanyl-L-histidine) is an endogenous dipeptide synthesized primarily in skeletal muscle and neural tissue via the enzyme carnosine synthase (ATPGD1), using beta-alanine and L-histidine as substrates. Its histidine imidazole ring and beta-alanine moiety together confer a unique combination of pH-buffering capacity, metal ion chelation, reactive oxygen species (ROS) scavenging, and anti-glycation activity within a single molecule — properties that underlie its broad biological effects across diverse tissue types.

At the molecular level, L-Carnosine acts as a non-enzymatic antioxidant capable of quenching hydroxyl radicals, superoxide anions, and singlet oxygen. It chelates divalent metal ions (particularly copper and zinc), preventing metal-catalyzed oxidative reactions. Critically, carnosine functions as an inhibitor of advanced glycation end-product (AGE) formation through its ability to react with reactive carbonyl intermediates such as methylglyoxal and malondialdehyde (MDA), a process termed "carbonyl quenching" or transglycation. This mechanism is directly relevant to its clinical effects in diabetic populations, where it reduces carboxymethyl lysine and pentosidine — established AGE biomarkers — along with circulating TNF-α2. The anti-glycation mechanism also likely underpins its neuroprotective applications, as AGE accumulation contributes to protein aggregation and neuroinflammation.

In the central nervous system, L-Carnosine's proposed mechanisms are multi-modal. It may enhance frontal lobe and temporal cortex neurological function, and its structural relationship to GABA (gamma-aminobutyric acid) through the homocarnosine pathway has been proposed as a mechanism for modulating inhibitory neurotransmission and potentially reducing cortical excitability1. Separately, its antioxidant and anti-glycation properties appear to support glutamatergic synaptic integrity, as improvements in executive function in schizophrenia were selectively observed in domains linked to NMDA receptor-dependent cognition — consistent with an indirect glutamate-modulatory mechanism rather than direct receptor binding3. L-Carnosine also significantly modulates the NF-κB / Nrf-2 axis: in oxaliplatin neuropathy, it reduced NF-κB by approximately 27%, TNF-α by 36.6%, and MDA by 51.8%, while increasing Nrf-2 by 38.7% and reducing caspase-3 activity by 49%14, demonstrating coordinated anti-inflammatory, antioxidant, and anti-apoptotic signaling.

Pharmacologically, L-Carnosine is absorbed orally and is subject to hydrolysis by the serum enzyme carnosinase (CN1) into its constituent amino acids, which can limit systemic bioavailability. Zinc chelation (as in polaprezinc) partially protects the dipeptide from carnosinase degradation and enhances mucosal residency time, which is relevant to its gastrointestinal applications7,9,19. The selective anti-inflammatory pattern observed in diabetic patients — TNF-α reduced without significant effects on IL-6 or IL-1β — suggests pathway-specific modulation rather than broad cytokine suppression2, and may reflect differential sensitivity of NF-κB target gene promoters to carnosine's carbonyl-quenching and metal-chelating activities.

§04Evidence & efficacy

Evidence base
297Studies
141Human
75Animal

L-Carnosine's clinical efficacy has been investigated across neurological, metabolic, cardiovascular, oncological, and gastrointestinal domains.

Autism Spectrum Disorder: 800 mg/day for 8 weeks significantly improved Gilliam Autism Rating Scale total score and its Behavior, Socialization, and Communication subscales, as well as Receptive One-Word Picture Vocabulary scores, compared to placebo in a double-blind RCT (n=31)1. In a separate trial, 500 mg/day improved sleep duration, parasomnias, and total sleep disorder scores in autistic children compared to placebo, without affecting core autism severity8.

Type 2 Diabetes: 1,000 mg/day for 12 weeks reduced fasting blood glucose by 13.1 mg/dL, HbA1c by 0.6%, triglycerides by 29.8 mg/dL, carboxymethyl lysine by 91.8 ng/mL, and TNF-α compared to placebo, alongside reductions in fat mass and increases in fat-free mass2. A systematic review and meta-analysis reported a statistically significant reduction in HbA1c (MD −1.25, 95% CI −2.49 to −0.022) across pooled diabetic studies18.

Schizophrenia / Cognitive Function: 2 g/day for 12 weeks may improve non-reversal set-shifting speed, strategic efficiency, and perseverative error rates on executive function tests relative to placebo3. A 24-week trial using up to 800 mg/day reported a significant improvement in attention scores at the higher dose (p=0.023), with executive function trends that did not reach significance across all domains4.

Chronic Heart Failure: 500 mg/day orodispersible for 6 months was associated with significant improvements in peak VO2 (p<0.0001), VO2 at anaerobic threshold, peak exercise workload, 6-minute walk test distance (p=0.014), and quality-of-life scores (p=0.039) compared to standard treatment alone6.

Gulf War Illness: Dose-escalation carnosine supplementation may improve cognitive performance on the WAIS-R digit symbol substitution test and appears to reduce IBS-associated diarrhea, though it did not significantly improve fatigue, pain, or physical activity outcomes5.

Chemotherapy-Induced Peripheral Neuropathy: 500 mg/day during oxaliplatin-based chemotherapy was associated with a reduction in grade 2 peripheral neuropathy incidence from 61.3% in controls to 3.3% in treated patients, accompanied by significant reductions in NF-κB, TNF-α, MDA, and caspase-3, and upregulation of Nrf-214.

Oral Mucositis: Zinc L-carnosine (polaprezinc) oral rinse appears to reduce incidence and severity of radiation- and chemotherapy-induced oral mucositis, lower analgesic requirements, and improve food intake without affecting tumor response rates7,10.

Gastrointestinal Applications: Zinc L-carnosine at 150 mg/day for 4 weeks may reduce aspirin-induced small bowel mucosal erosions and ulcers as assessed by capsule endoscopy19. Zinc L-carnosine liquid formulation appears non-inferior to thickened formula for management of infant regurgitation9. Several trials evaluating GERD maintenance and periodontal applications are currently in active development11,17.

§05Safety

L-Carnosine has demonstrated a favorable tolerability profile across a wide range of human clinical populations, including children, adults with metabolic disease, cancer patients, and individuals with psychiatric conditions. The majority of trials reported no significant adverse events attributable to L-carnosine supplementation1,2,5,6,7,8,14,19.

In one notable exception, the schizophrenia trial by Chengappa et al. reported a higher rate of adverse events in the L-carnosine group (30%) compared to placebo (14%), though laboratory indices remained within acceptable ranges and no specific adverse events were enumerated3. This signal warrants attention in larger trials. A separate schizophrenia trial using up to 800 mg/day over 24 weeks reported no significant safety concerns4.

In pediatric populations, 500 mg/day in children with autism was reported to produce no adverse effects on anthropometric indices over 2 months8, and zinc L-carnosine liquid formulation was described as safe in an infant cohort9. In oncology settings, L-carnosine co-administered with the FOLFOX-6 chemotherapy regimen did not introduce additional toxicities beyond the standard protocol14, and polaprezinc oral rinse showed no negative impact on tumor response rates in head and neck cancer patients undergoing radiochemotherapy7.

In a Gulf War Illness trial, dose escalation up to 1,500 mg/day was generally well-tolerated, and the compound was associated with a reduction in IBS-related diarrhea, suggesting a favorable gastrointestinal profile5. No drug interactions, contraindications, or organ toxicity signals were reported across any included studies. Long-term safety data beyond 6 months is an area of active investigation.

§06History

L-Carnosine was first isolated from beef extract in 1900 by the Russian chemist Vladimir Gulevich and subsequently identified as a ubiquitous component of vertebrate skeletal muscle and brain tissue. Early research in the mid-20th century characterized its role as a pH buffer during intense muscular activity and established its antioxidant properties. Interest in carnosine as a therapeutic agent accelerated during the 1990s and 2000s as the role of oxidative stress and advanced glycation end-products (AGEs) in aging, neurodegeneration, and metabolic disease became increasingly well-characterized.

A landmark double-blind RCT published in 2002 established L-Carnosine as a candidate neurological therapeutic, demonstrating significant improvements in autistic children across behavioral, social, and communication domains1. Concurrently, the zinc-chelated form — polaprezinc (zinc L-carnosine) — was developed and approved in Japan in the 1990s as a treatment for gastric ulcers under the brand name Promac, representing the first regulatory approval of a carnosine-based compound. Its mucosal protective properties were subsequently studied in radiation-induced oral mucositis7, aspirin-induced small bowel injury19, and infant gastroesophageal reflux9.

Research expanded through the 2010s to include metabolic applications in type 2 diabetes2, cardiovascular applications in heart failure6, and neuropsychiatric applications in schizophrenia3. The current research landscape spans multiple registered trials examining visceral adiposity, NAFLD, periodontal health, and pediatric gastrointestinal disorders11,12,13,15,17, reflecting a broad and actively developing translational program across multiple therapeutic areas.

§07References